中南药学2024,Vol.22Issue(5) :1311-1316.DOI:10.7539/j.issn.1672-2981.2024.05.031

过氧化物酶体增殖活化因子受体γ及其激动剂在类风湿关节炎中的作用研究进展

Research progress in the role of peroxisome proliferator-activated receptor-γ and its agonists in rheumatoid arthritis

陈娜 臧雷 刘芳
中南药学2024,Vol.22Issue(5) :1311-1316.DOI:10.7539/j.issn.1672-2981.2024.05.031

过氧化物酶体增殖活化因子受体γ及其激动剂在类风湿关节炎中的作用研究进展

Research progress in the role of peroxisome proliferator-activated receptor-γ and its agonists in rheumatoid arthritis

陈娜 1臧雷 1刘芳1
扫码查看

作者信息

  • 1. 中国人民解放军陆军军医大学第一附属医院药剂科,重庆 400038
  • 折叠

摘要

类风湿关节炎是一种以多关节滑膜炎为主要特征的自身免疫性疾病,其发病机制尚未完全阐明.过氧化物酶体增殖活化因子受体γ(PPARγ)是一类配体激活的核转录因子超家族成员,在免疫调节、炎症控制和骨稳定中发挥重要功能.因此,研究PPARγ在类风湿关节炎中发挥的作用具有重要意义.本文就PPARγ在类风湿关节炎中的作用进行综述,并讨论基于PPARγ靶点治疗药物的发展情况,以期为抗类风湿关节炎新药研发提供思路和参考.

Abstract

Rheumatoid arthritis is an autoimmune disease characterized by polyarticular synovitis,whose pathogenesis has not been fully elucidated.Peroxisome proliferator-activated receptor-γ(PPARγ)is a member of the ligand-activated nuclear transcription factor superfamily,which plays an important role in immune regulation,inflammation control and bone stability.It is important to determine the role of PPARγ in rheumatoid arthritis.This article reviewed the role of PPARγ in rheumatoid arthritis,and the development of therapeutic drugs based on the target of PPARγ,so as to provide reference for the development of new drugs for rheumatoid arthritis.

关键词

类风湿关节炎/过氧化物酶体增殖活化因子受体γ/炎症控制/免疫调节/骨稳定

Key words

rheumatoid arthritis/peroxisome proliferator-activated receptor-y/inflammation control/immune regulation/bone stability

引用本文复制引用

基金项目

重庆市自然科学基金(CSTB2022NSCQ-MSX0202)

重庆市科卫联合中医药项目(2019ZY023488)

出版年

2024
中南药学
湖南省药学会

中南药学

CSTPCD
影响因子:0.736
ISSN:1672-2981
参考文献量44
段落导航相关论文